Advisors, including human performance expert
Jamie Wheal and mental health advocate Ben
Nemtin, join Numinus to help guide and inform company
leadership
VANCOUVER, BC, Oct. 14, 2020 /CNW/ - Recognized and respected
leaders from technology, pharmacology, and health have joined
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI) as
members of the Company's General Advisory Council. Drawing on
experience across a broad range of specialities including
psychedelic medicine, mental health advocacy, performance
optimization, and digital healthcare, the multidisciplinary council
will provide unique insight and guidance to support Numinus'
mission of creating an ecosystem of health solutions centred on
safe, evidence-based, accessible psychedelic-assisted
psychotherapy.
"As we continue to develop new approaches and new ways of
thinking about mental healthcare, diverse opinions and experiences
will be key," says Payton Nyquvest,
Numinus CEO. "Our council members bring a wealth of knowledge from
each of their respective communities, and we're proud to be working
with them to help address the universal desire to heal and be
well."
Members of the advisory council include:
- Jamie Wheal, Founder & Executive Director, Flow Genome
Project: Wheal is a Pulitzer Prize nominee, bestselling author
and Founder of the Flow Genome Project, an organization dedicated
to research and training of ultimate human performance. Wheal's
peak performance training entails work with clients including
members of the US Naval War College and
technology executives, among others.
- Ben Nemtin, Co-founder, The
Buried Life: Nemtin is a #1 New York
Times bestselling author who has been featured on The Today
Show, The Oprah Winfrey Show, CNN, Inc., NBC News and more. After
experiencing an unexpected depression in his university years,
Nemtin has gone on to become one of the World's Best Motivational
Speakers (Global Gurus, 2020), helping people around the world
achieve their goals and normalize the conversation around mental
health.
- Dennis McKenna, PhD,
Ethnopharmacologist, Co-founder of the Heffter Research Institute,
and Founder of the McKenna Academy: McKenna is an
ethnopharmacologist with over 40 years of research experience and
was a key investigator on the Hoasca Project – the first biomedical
investigation of ayahuasca, involving researchers from nine
universities and research institutions around the world.
- Pamela Hadfield, Co-founder,
HelloMD: Hadfield is an experienced entrepreneur and thought
leader within the cannabis space. She is the Co-founder of HelloMD,
a digital telehealth and educational platform for cannabis and
complementary healthcare, and the exclusive partner of Shoppers
Drug Mart.
- Nichol Bradford, Co-founder
& Executive Director, Transformative Technology Lab and CEO,
Willow Group: Bradford is
fascinated by human potential and how technology can help expand
our perceived individual limitations. Through Transformative
Technology Lab and Willow, her work is focused on advancing
science-based hardware and software with the potential to produce
positive changes in the human psychological experience.
"I've spent my career focused on how psychedelic substances can
supplement existing treatment options for mental healthcare," says
Dennis McKenna, Ethnopharmacologist
and Co-founder of the Heffter Research Institute, a US non-profit
working closely with leading research groups including Johns Hopkins University to support psychedelic
research. "I look forward to working with Numinus to advance the
use of these substances in safe, controlled, therapeutic
environments to treat mental health, addiction and trauma, as well
as address the costs of unmet human potential."
Echoing McKenna's support, Pamela
Hadfield states "Psychedelic-assisted psychotherapy, which
is quickly becoming a reality, is the biggest mental
healthcare disruptor of our generation. Similar to the coming-out
party for cannabis, psychedelics are about to be accepted by the
mainstream, but with an even greater, far-reaching, positive
societal impact. I'm thrilled to support Numinus as a leader in the
field with research backed initiatives, best business practices and
their overall sense of purpose and integrity." Ben Nemtin adds, "With more and more people
struggling with depression and anxiety amid the COVID-19 pandemic,
I couldn't be more proud to support Numinus' mission to make
psychedelic-assisted psychotherapies accessible to all."
Advisory Council Members
Dennis McKenna,
Ethnopharmacologist, Co-founder of Heffter Research Institute,
Founder of McKenna Academy
McKenna brings over 40 years of
experience conducting research in ethnopharmacology. He is a
Founding Board Member of the Heffter Research Institute and a
former key investigator on the Hoasca Project, the first biomedical
investigation of ayahuasca. McKenna has taught courses on
Ethnopharmacology and Plants in Human Affairs for 17 years as an
adjunct Assistant Professor in the Center for Spirituality and
Healing at the University of Minnesota.
In collaboration with colleagues in Canada and the US, he incorporated a new
non-profit, the McKenna Academy of Natural Philosophy.
heffter.org; LinkedIn: Dennis
McKenna
Jamie Wheal, Founder & Executive Director, The Flow
Genome Project
Wheal is a bestselling author, Pulitzer Prize nominee and founder
of the Flow Genome Project, an international organization dedicated
to research and training of ultimate human performance. Since its
inception in 2011, the organization has become the leading voice of
evidence-based peak performance. Wheal is an expert on peak
performance and leadership, specializing in the neuroscience and
application of Flow states.
flowgenomeproject.com, LinkedIn: Jamie Wheal
Ben Nemtin, Co-founder, The
Buried Life
Nemtin is the #1 New York
Times bestselling author of What Do you Want to Do Before
You Die?, co-founder of the Buried Life movement and a mental
health advocate. Nemtin was forced to drop out of university due to
depression and in an effort to feel more alive, he and his three
friends made a list of '100 things to do before you die' and for
every list item they accomplished, they helped a complete stranger
cross something off their bucket list. Oprah Winfrey declared their mission "truly
inspiring". Nemtin is recognized as one of the 'World's Best
Motivational Speakers' as well as 'World's Top Organizational
Culture Thought Leaders' by Global Gurus and regularly speaks to
Fortune 100 leadership teams and business conferences around the
world.
www.bennemtin.com; LinkedIn: Ben
Nemtin
Pamela Hadfield, Co-founder,
HelloMD
Hadfield is an entrepreneur and thought leader in
the cannabis space. She became a cannabis advocate after finding
relief from debilitating migraines using medical cannabis. After
cannabis transformed her health, she dedicated her time and efforts
to helping others with alternative healthcare approaches, including
cannabis. Hadfield is the co-founder of HelloMD, a digital
telehealth and educational platform for cannabis consumers and
people seeking complementary care.
hellomd.ca; LinkedIn: Pamela
Hadfield
Nichol Bradford, Executive
Director, Transformative Technology Lab & CEO, Willow
Bradford is CEO of the Willow Group and Executive Director of the
Transformative Technology Lab. She is a former senior executive in
the video game industry responsible for strategy, operations and
marketing for major brands, including Disney, Vivideni and
Activision Blizzard. Bradford is also a fellow of the British
American Project, a former term member of the Council on Foreign
Relations and served on the board of the Brandon Marshall Foundation for Mental
Health.
transtechlab.org, willowgroup.co; LinkedIn: Nichol Bradford
About Numinus Wellness Inc.
Numinus Wellness Inc.
(TSXV: NUMI) is a mental health and wellness company creating an
ecosystem of solutions centred around safe, evidence-based,
accessible psychedelic-assisted psychotherapy to help people heal
and be well.
Numinus Health is dedicated to delivering innovative
treatments to address physical, mental, and emotional health,
through clinics and virtual services.
Numinus R&D is conducting implementation science
and leveraging partnerships to beta-test and refine optimal models
of psychedelic-assisted psychotherapy delivery, setting the stage
for approved routine use in mental health and wellness care.
Numinus Bioscience is focused on developing testing
methods and effective formulas for the evolving psychedelics space.
Health Canada licences, scientific
expertise, and new technologies facilitate ongoing innovation, and
high-throughput contract services generate established revenue.
Learn more at: numinus.ca and follow us
on Facebook, Twitter, and Instagram.
Forward Looking Statements
This news release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements."
Forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward looking statements. Such risks and uncertainties include,
among others, dependence on obtaining and maintaining regulatory
approvals, including acquiring and renewing federal, provincial,
municipal, local or other licenses and any inability to obtain all
necessary governmental approvals licenses and permits to operate
and expand the Company's facilities; regulatory or political change
such as changes in applicable laws and regulations, including
federal and provincial legalization, due to inconsistent public
opinion, perception of the medical-use and adult-use marijuana
industry, bureaucratic delays or inefficiencies or any other
reasons; any other factors or developments which may hinder market
growth; the Company's limited operating history and lack of
historical profits; reliance on management; the Company's
requirements for additional financing, and the effect of capital
market conditions and other factors on capital availability;
competition, including from more established or better financed
competitors; and the need to secure and maintain corporate
alliances and partnerships, including with research and development
institutions, customers and suppliers. These factors should be
considered carefully, and readers are cautioned not to place undue
reliance on such forward-looking statements. Although the Company
has attempted to identify important risk factors that could cause
actual actions, events or results to differ materially from those
described in forward-looking statements, there may be other risk
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in forward-looking statements. The Company has no
obligation to update any forward-looking statement, even if new
information becomes available as a result of future events, new
information or for any other reason except as required by
law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/numinus-appoints-multidisciplinary-global-leaders-to-its-general-advisory-council-301151740.html
SOURCE Numinus Wellness Inc.